胆道がんの世界市場レポート 2025年

胆道がん市場規模は、今後数年間で力強い成長が見込まれます。2029年にはCAGR7.3％で9億5,000万米ドルに成長します。予測期間の成長は、ライフスタイルの変化、認知度の向上、早期発見の取り組み、有利な償還政策、政府の支援政策などに起因すると考えられます。この期間に予想される主な動向には、診断と治療における技術的進歩、免疫療法の採用、精密医療に対する需要の高まり、治療アプローチの進化、バイオマーカーに基づく治療の進歩などがあります。

肥満の有病率の上昇が胆道がん市場の成長を牽引すると予想されます。肥満は、健康に悪影響を及ぼす過剰な脂肪蓄積を特徴とする慢性的な病状です。肥満率の増加には、運動不足、心理的影響、加齢、遺伝的・生物学的要因など、いくつかの要因が関与しています。肥満は慢性炎症、インスリン抵抗性、過剰な胆汁酸分泌を促進し、DNA損傷や腫瘍形成につながります。また、ホルモンバランスや代謝を乱し、胆道内にがんが発生しやすい環境を作り出します。例えば、2023年9月、米国の政府機関である疾病対策予防センター（CDC）によると、2022年、成人の肥満率が35％以上の州は、2021年の19州から22州に増加しました。その結果、肥満の蔓延が胆道がん市場の拡大に拍車をかけています。

胆道がん市場の主要企業は、治療効果と患者の転帰を改善するために先進的な併用療法を開発しています。併用療法は、2つ以上の薬剤や治療アプローチを同時に使用して効果を高めるものです。例えば、2023年11月にMerck &Co.Inc.は、KEYTRUDA（ペムブロリズマブ）とゲムシタビンおよびシスプラチンを併用した局所進行切除不能または転移性胆道がん（BTC）患者の治療薬として米国食品医薬品局（FDA）の承認を取得しました。この承認は、第3相KEYNOTE-966試験の結果に基づいており、化学療法単独と比較して全生存期間が統計学的に有意に改善し、死亡リスクが17％減少しました。併用療法を受けた患者の全生存期間中央値は12.7カ月であり、化学療法単独群では10.9カ月でした。これは、この課題であるがんの治療選択肢を大きく前進させるものです。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場- マクロ経済シナリオ金利、インフレ、地政学、新型コロナウイルス感染症の影響と回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界胆道がんPESTEL分析（政治、社会、技術、環境、法的要因、促進要因と抑制要因）
• 最終用途産業の分析
• 世界の胆道がん市場：成長率分析
• 世界の胆道がん市場の実績：規模と成長, 2019-2024
• 世界の胆道がん市場の予測：規模と成長, 2024-2029, 2034F
• 世界胆道がん総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界の胆道がん市場がんの種類別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 肝内胆管がん
• 肝外胆管がん
• 胆嚢がん
• 世界の胆道がん市場治療別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 化学療法
• 標的療法
• 免疫療法
• 世界の胆道がん市場：エンドユーザー別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院
• 専門がんセンター
• 外来手術センター
• その他のエンドユーザー
• 世界の胆道がん市場肝内胆管がんの種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 末梢肝内胆管がん
• 肝門部胆管がん
• 世界の胆道がん市場肝外胆管がんの種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 門脈周囲胆管がん
• 遠位胆管がん
• 世界の胆道がん市場胆嚢がんの種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 局所性胆嚢がん
• 進行胆嚢がん

第7章 地域別・国別分析

• 世界の胆道がん市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界の胆道がん市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 胆道がん市場：競合情勢
• 胆道がん市場：企業プロファイル
  • Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • F. Hoffmann-La Roche Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Bayer AG Overview, Products and Services, Strategy and Financial Analysis
  • Bristol-Myers Squibb Company Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• AstraZeneca Plc
• Eli Lily and Company
• Boehringer Ingelheim International GmbH
• Eisai Co. Ltd.
• Servier Pharmaceuticals
• Jazz Pharmaceuticals plc
• Incyte Corporation
• BeiGene LTD.
• Zymeworks
• Basilea Pharmaceutica Ltd.
• Taiho Oncology Inc.
• RenovoRx Inc.
• TransThera Sciences Inc.
• QED Therapeutics Inc.
• Helsinn Group

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• 胆道がん市場2029：新たな機会を提供する国
• 胆道がん市場2029：新たな機会を提供するセグメント
• 胆道がん市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Biliary tract cancer (BTC), also known as cholangiocarcinoma, is a rare malignancy that develops in the bile ducts, gallbladder, or ampulla of Vater. This cancer disrupts bile flow, which is essential for digestion and waste elimination. Research and treatment efforts focus on early detection, advancing therapeutic options, and improving survival rates for affected patients.

The primary types of biliary tract cancer include intrahepatic bile duct cancer, extrahepatic bile duct cancer, and gallbladder cancer. Intrahepatic cholangiocarcinoma is a rare liver cancer affecting the bile ducts, potentially leading to bile flow obstruction. Treatment options include chemotherapy, targeted therapy, and immunotherapy, catering to various end users such as hospitals, specialty cancer centers, ambulatory surgical centers, and others.

The biliary tract cancer market research report is one of a series of new reports from The Business Research Company that provides biliary tract cancer market statistics, including the biliary tract cancer industry global market size, regional shares, competitors with the biliary tract cancer market share, detailed biliary tract cancer market segments, market trends, and opportunities, and any further data you may need to thrive in the biliary tract cancer industry. This biliary tract cancer market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The biliary tract cancer market size has grown strongly in recent years. It will grow from $0.67 billion in 2024 to $0.72 billion in 2025 at a compound annual growth rate (CAGR) of 7.5%. The growth during the historic period can be attributed to the rising incidence of biliary tract cancer, increasing demand for effective therapies, a surge in risk factors such as obesity, an aging population, and greater investment in research and development.

The biliary tract cancer market size is expected to see strong growth in the next few years. It will grow to $0.95 billion in 2029 at a compound annual growth rate (CAGR) of 7.3%. The growth in the forecast period can be attributed to lifestyle changes, increasing awareness, early detection initiatives, favorable reimbursement policies, and supportive government policies. Key trends expected during this period include technological advancements in diagnosis and treatment, the adoption of immunotherapy, rising demand for precision medicine, evolving treatment approaches, and advancements in biomarker-based therapies.

The rising prevalence of obesity is expected to drive the growth of the biliary tract cancer market. Obesity is a chronic medical condition characterized by excessive fat accumulation that negatively impacts health. Several factors contribute to the increasing obesity rates, including physical inactivity, psychological influences, aging, and genetic or biological factors. Obesity promotes chronic inflammation, insulin resistance, and excessive bile acid secretion, leading to DNA damage and tumor formation. It also disrupts hormonal balance and metabolism, creating a cancer-prone environment in the biliary tract. For example, in September 2023, the Centers for Disease Control and Prevention (CDC), a US-based government agency, reported that in 2022, the number of states with an adult obesity rate of 35% or higher increased to 22, up from 19 in 2021. As a result, the growing prevalence of obesity is fueling the expansion of the biliary tract cancer market.

Leading companies in the biliary tract cancer market are developing advanced combination therapies to improve treatment efficacy and patient outcomes. Combination therapy involves using two or more medications or treatment approaches simultaneously to enhance effectiveness. For instance, in November 2023, Merck & Co. Inc., a US-based pharmaceutical company, received U.S. Food and Drug Administration (FDA) approval for KEYTRUDA (pembrolizumab) in combination with gemcitabine and cisplatin for treating patients with locally advanced unresectable or metastatic biliary tract cancer (BTC). This approval was based on results from the Phase 3 KEYNOTE-966 trial, which demonstrated a statistically significant improvement in overall survival, reducing the risk of death by 17% compared to chemotherapy alone. Patients receiving the combination therapy had a median overall survival of 12.7 months, compared to 10.9 months for those on chemotherapy alone, marking a major advancement in treatment options for this challenging cancer.

In December 2022, Jazz Pharmaceuticals plc, an Ireland-based pharmaceutical company, partnered with Zymeworks Inc. to develop and commercialize zanidatamab, a HER2-targeted bispecific antibody. This collaboration was driven by promising results from the HERIZON-BTC-01 pivotal trial for biliary tract cancers. Zymeworks Inc. is a Canada-based biotechnology company specializing in the development of biliary tract cancer drugs.

Major players in the biliary tract cancer market are Pfizer Inc., F. Hoffmann-La Roche Ltd., Merck & Co. Inc., Bayer AG, Bristol-Myers Squibb Company, AstraZeneca Plc, Eli Lily and Company, Boehringer Ingelheim International GmbH, Eisai Co. Ltd., Servier Pharmaceuticals, Jazz Pharmaceuticals plc, Incyte Corporation, BeiGene LTD., Zymeworks, Basilea Pharmaceutica Ltd., Taiho Oncology Inc., RenovoRx Inc., TransThera Sciences Inc., QED Therapeutics Inc., and Helsinn Group.

North America was the largest region in the biliary tract cancer market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in biliary tract cancer report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the biliary tract cancer market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The biliary tract cancer market consists of revenues earned by entities by providing services such as diagnosis and screening services, supportive care, clinical trials, and research. The market value includes the value of related goods sold by the service provider or included within the service offering. The biliary tract cancer market also includes sales of surgical instruments, pain management medications, and diagnostic tools. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Biliary Tract Cancer Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on biliary tract cancer market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for biliary tract cancer ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The biliary tract cancer market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Cancer Type: Intrahepatic Bile Duct Cancer; Extrahepatic Bile Duct Cancer; Gallbladder Cancer
• 2) By Treatment: Chemotherapy; Targeted Therapy; Immunotherapy
• 3) By End-User: Hospitals; Specialty Cancer Centres; Ambulatory Surgical Centres; Other End-Users
• Subsegments:
• 1) By Intrahepatic Bile Duct Cancer: Peripheral Intrahepatic Bile Duct Cancer; Hilar Intrahepatic Bile Duct Cancer
• 2) By Extrahepatic Bile Duct Cancer: Perihilar Bile Duct Cancer; Distal Bile Duct Cancer
• 3) By Gallbladder Cancer: Localized Gallbladder Cancer; Advanced Gallbladder Cancer
• Companies Mentioned: Pfizer Inc.; F. Hoffmann-La Roche Ltd.; Merck & Co. Inc.; Bayer AG; Bristol-Myers Squibb Company
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Biliary Tract Cancer Market Characteristics

3. Biliary Tract Cancer Market Trends And Strategies

4. Biliary Tract Cancer Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market

5. Global Biliary Tract Cancer Growth Analysis And Strategic Analysis Framework

• 5.1. Global Biliary Tract Cancer PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Biliary Tract Cancer Market Growth Rate Analysis
• 5.4. Global Biliary Tract Cancer Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Biliary Tract Cancer Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Biliary Tract Cancer Total Addressable Market (TAM)

6. Biliary Tract Cancer Market Segmentation

• 6.1. Global Biliary Tract Cancer Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Intrahepatic Bile Duct Cancer
• Extrahepatic Bile Duct Cancer
• Gallbladder Cancer
• 6.2. Global Biliary Tract Cancer Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Chemotherapy
• Targeted Therapy
• Immunotherapy
• 6.3. Global Biliary Tract Cancer Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals
• Specialty Cancer Centres
• Ambulatory Surgical Centres
• Other End-Users
• 6.4. Global Biliary Tract Cancer Market, Sub-Segmentation Of Intrahepatic Bile Duct Cancer, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Peripheral Intrahepatic Bile Duct Cancer
• Hilar Intrahepatic Bile Duct Cancer
• 6.5. Global Biliary Tract Cancer Market, Sub-Segmentation Of Extrahepatic Bile Duct Cancer, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Perihilar Bile Duct Cancer
• Distal Bile Duct Cancer
• 6.6. Global Biliary Tract Cancer Market, Sub-Segmentation Of Gallbladder Cancer, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Localized Gallbladder Cancer
• Advanced Gallbladder Cancer

7. Biliary Tract Cancer Market Regional And Country Analysis

• 7.1. Global Biliary Tract Cancer Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Biliary Tract Cancer Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Biliary Tract Cancer Market

• 8.1. Asia-Pacific Biliary Tract Cancer Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Biliary Tract Cancer Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Biliary Tract Cancer Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Biliary Tract Cancer Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Biliary Tract Cancer Market

• 9.1. China Biliary Tract Cancer Market Overview
• 9.2. China Biliary Tract Cancer Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Biliary Tract Cancer Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Biliary Tract Cancer Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Biliary Tract Cancer Market

• 10.1. India Biliary Tract Cancer Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Biliary Tract Cancer Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Biliary Tract Cancer Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Biliary Tract Cancer Market

• 11.1. Japan Biliary Tract Cancer Market Overview
• 11.2. Japan Biliary Tract Cancer Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Biliary Tract Cancer Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Biliary Tract Cancer Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Biliary Tract Cancer Market

• 12.1. Australia Biliary Tract Cancer Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Biliary Tract Cancer Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Biliary Tract Cancer Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Biliary Tract Cancer Market

• 13.1. Indonesia Biliary Tract Cancer Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Biliary Tract Cancer Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Biliary Tract Cancer Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Biliary Tract Cancer Market

• 14.1. South Korea Biliary Tract Cancer Market Overview
• 14.2. South Korea Biliary Tract Cancer Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Biliary Tract Cancer Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Biliary Tract Cancer Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Biliary Tract Cancer Market

• 15.1. Western Europe Biliary Tract Cancer Market Overview
• 15.2. Western Europe Biliary Tract Cancer Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Biliary Tract Cancer Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Biliary Tract Cancer Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Biliary Tract Cancer Market

• 16.1. UK Biliary Tract Cancer Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Biliary Tract Cancer Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Biliary Tract Cancer Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Biliary Tract Cancer Market

• 17.1. Germany Biliary Tract Cancer Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Biliary Tract Cancer Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Biliary Tract Cancer Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Biliary Tract Cancer Market

• 18.1. France Biliary Tract Cancer Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Biliary Tract Cancer Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Biliary Tract Cancer Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Biliary Tract Cancer Market

• 19.1. Italy Biliary Tract Cancer Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Biliary Tract Cancer Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Biliary Tract Cancer Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Biliary Tract Cancer Market

• 20.1. Spain Biliary Tract Cancer Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Biliary Tract Cancer Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Biliary Tract Cancer Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Biliary Tract Cancer Market

• 21.1. Eastern Europe Biliary Tract Cancer Market Overview
• 21.2. Eastern Europe Biliary Tract Cancer Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Biliary Tract Cancer Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Biliary Tract Cancer Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Biliary Tract Cancer Market

• 22.1. Russia Biliary Tract Cancer Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Biliary Tract Cancer Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Biliary Tract Cancer Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Biliary Tract Cancer Market

• 23.1. North America Biliary Tract Cancer Market Overview
• 23.2. North America Biliary Tract Cancer Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Biliary Tract Cancer Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Biliary Tract Cancer Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Biliary Tract Cancer Market

• 24.1. USA Biliary Tract Cancer Market Overview
• 24.2. USA Biliary Tract Cancer Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Biliary Tract Cancer Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Biliary Tract Cancer Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Biliary Tract Cancer Market

• 25.1. Canada Biliary Tract Cancer Market Overview
• 25.2. Canada Biliary Tract Cancer Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Biliary Tract Cancer Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Biliary Tract Cancer Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Biliary Tract Cancer Market

• 26.1. South America Biliary Tract Cancer Market Overview
• 26.2. South America Biliary Tract Cancer Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Biliary Tract Cancer Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Biliary Tract Cancer Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Biliary Tract Cancer Market

• 27.1. Brazil Biliary Tract Cancer Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Biliary Tract Cancer Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Biliary Tract Cancer Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Biliary Tract Cancer Market

• 28.1. Middle East Biliary Tract Cancer Market Overview
• 28.2. Middle East Biliary Tract Cancer Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Biliary Tract Cancer Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Biliary Tract Cancer Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Biliary Tract Cancer Market

• 29.1. Africa Biliary Tract Cancer Market Overview
• 29.2. Africa Biliary Tract Cancer Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Biliary Tract Cancer Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Biliary Tract Cancer Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Biliary Tract Cancer Market Competitive Landscape And Company Profiles

• 30.1. Biliary Tract Cancer Market Competitive Landscape
• 30.2. Biliary Tract Cancer Market Company Profiles
  • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. F. Hoffmann-La Roche Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Bayer AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Bristol-Myers Squibb Company Overview, Products and Services, Strategy and Financial Analysis

31. Biliary Tract Cancer Market Other Major And Innovative Companies

• 31.1. AstraZeneca Plc
• 31.2. Eli Lily and Company
• 31.3. Boehringer Ingelheim International GmbH
• 31.4. Eisai Co. Ltd.
• 31.5. Servier Pharmaceuticals
• 31.6. Jazz Pharmaceuticals plc
• 31.7. Incyte Corporation
• 31.8. BeiGene LTD.
• 31.9. Zymeworks
• 31.10. Basilea Pharmaceutica Ltd.
• 31.11. Taiho Oncology Inc.
• 31.12. RenovoRx Inc.
• 31.13. TransThera Sciences Inc.
• 31.14. QED Therapeutics Inc.
• 31.15. Helsinn Group

32. Global Biliary Tract Cancer Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Biliary Tract Cancer Market

34. Recent Developments In The Biliary Tract Cancer Market

35. Biliary Tract Cancer Market High Potential Countries, Segments and Strategies

• 35.1 Biliary Tract Cancer Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Biliary Tract Cancer Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Biliary Tract Cancer Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer